PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ketazolam→

Ketazolam PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
27223-35-4
Molecular formula
C20H17ClN2O3
Molecular weight
368.814 g/mol
Drug class
Benzodiazepine anxiolyticpositive allosteric modulator of GABAA receptors
Mechanism of action
Binds to the benzodiazepine site on GABAA receptor complexes and enhances the effect of endogenous GABA, increasing chloride-channel opening and neuronal inhibition. This produces anxiolytic, sedative, muscle-relaxant and anticonvulsant effects.
Indications / reported uses
  • Treatment of anxiety disorders and symptomatic relief of severe anxiety, according to local product authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/Ketazolam · https://meshb.nlm.nih.gov/record/ui?ui=D007571

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ketazolam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ketazolam Permitted Daily Exposure (PDE) report (the Ketazolam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ketazolam Occupational Exposure Limit (OEL) report (the Ketazolam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.